122. Assessment of Cognitive Function in Patients with Neuromyelitis Optica Spectrum Disorders (NMOSD) Compared to Patients with Multiple Sclerosis
Dmitry Kasatkin,Saule Turuspekova,Ekaterina Vekhina,Klara Almakhanova
DOI: https://doi.org/10.1016/j.msard.2024.106083
IF: 4.808
2024-12-16
Multiple Sclerosis and Related Disorders
Abstract:Background/Objective(s) Demyelinating diseases of the central nervous system (CNS), including neuromyelitis optica spectrum disorders (NMOSD), can often lead to cognitive decline already in the early stages, resulting in social and everyday disadaptation and reduced quality of life. Material(s) and Method(s) 15 NMOSD patients (Wingerchuk criteria,2015) included 3 men and 12 women, median age 37.44 years [LQ29.41;UQ58.61]. 8 (53%) were seropositive for aquaporin-4 antibodies. Three received pathogenetic therapy (2 anti-IL-6, 1 anti-CD20), while 12 were on off-label treatments. MRI showed that 60% had up to 10 nonspecific foci. Median age at onset was 35.21 years [LQ25.99;UQ53.54], median disease duration was 5.54 years, and mean exacerbation rate was 7.4 per year. Isolated optic neuritis occurred in 4, transverse myelitis in 5, and combined lesions in 6. The MS group (MacDonald criteria,2017) also had 15 patients (3 men,12 women), median age 37.75 years [LQ29.5;UQ58.8]. Their median disease duration was 9.6 years, with an exacerbation rate of 1 per year and a median EDSS score of 4.5 [LQ1.75;UQ5.25]. All were on therapy, with MRI revealing focal lesions in all cases. Cognitive functions were assessed using MoCA, SDMT, and PASAT; anxiety and depression were evaluated with Hamilton scales. Result(s) Anxiety and depression were present in 75%. According to the MoCA-test, the median score in the group of patients with NMOSD was 24 [LQ22; UQ25], in the MS group — 26 [LQ21; UQ28]. Median CogEval Z-value (SDMT) -1.48 [LQ-2.12; UQ-0.78] in the group with NMOSD and -2.98 [LQ-3.26; UQ-1.87] in the MS group (p≤0.01). In the first and second PASAT attempts, the median z-value among the NMOSD was -1.50 [LQ-2.26; UQ0.08] and -0.56 [LQ-2.85; UQ-0.20], respectively, with MS – -0.87 [LQ-2.3; UQ-0.002] and -1.19 [LQ-1.9; UQ -0,57] (p>0.05). Conclusion(s) Patients with NMOSD and MS showed below-average Z-scores compared to the healthy population, standardized by sex, age, and education level, but less decrease in attention and processing speed was observed among patients with NMOSD as measured by the Cogeval Test (SDMT) (p≤0.01). According to the analysis of the PASAT z-value results, patients with CSNM and MS have approximately the same level of decreased attention, memory, and processing speed (p>0.05). Further research, sample expansion, and development/inclusion of tests that are not related to visual function but are standardized by age, sex, and education are needed.
clinical neurology